Masimo (NASDAQ:MASI) (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.
In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications. The company has expanded into consumer health with wearable devices capable of measuring oxygen saturation, pulse rate, and other vital signs, supporting the growing trend toward home-based care and telehealth. Masimo’s software solutions enable real-time data analytics and alerts, allowing clinicians to detect patient deterioration earlier and improve workflow efficiency.
Headquartered in Irvine, California, Masimo operates in more than 100 countries through a combination of direct sales forces, distributors, and strategic partnerships. Key markets include North America, Europe, Asia-Pacific, and Latin America, where its products are used in hospitals, surgical centers, and home health environments. The company has established regional offices in Europe, the Middle East, and Asia to support local regulatory approvals and provide customer training and technical service.
Founded in 1989 by Joe Kiani, who serves as chairman and chief executive officer, Masimo has built a reputation for innovation and has received numerous industry awards. Under Kiani’s leadership, the company has invested heavily in research and development, filing hundreds of patents to advance noninvasive monitoring technology. This focus on innovation and quality has driven Masimo’s growth and positioned it as a leader in patient monitoring worldwide.
